Peak Pharmaceuticals, Inc. announced the development and plans for release and marketing of Canna-Pet(r) Advanced120, a new product targeting small to mid-sized animals. Formulated with Canna-Pet(r) Advanced, the new 120mg product targets delivery of the entire cannabinoid profile of hemp, including CBD and terpenes. The Canna-Pet(r) Advanced120 is designed for small to mid-sized pets, and would be an appropriate supplement for all cat and dog breeds.

The Canna-Pet(r) Advanced supplement was prepared based on in-house data and customer feedback, including responses from a recent customer survey. The formulation will first appear in the Canna-Pet(r) Advanced120 product, and later this year the company plans to include it in a new line of biscuit treats. The Canna-Pet(r) Advanced120 supplements are being produced in a cGMP manufacturing facility to ensure the level of product quality and consistency, a cornerstone of Peak Pharma's product philosophy.

The Advanced formula includes proprietary ratios of hemp-derived cannabinoids and terpenes, and the manufacturing process is designed to produce a supplement that mimics as closely as possible the phytochemical profile of the hemp plant.